Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: KZAP who wrote (77275)	5/31/2002 8:17:27 PM
From: dacoola	Respond to of 122087

It's a shame that you are not looked at with all of the "News Tomorrow" and "sales announced next week" type posts on RB for the past two years. Whatta joke.... Happy investing.

To: KZAP who wrote (77275)	6/26/2002 11:26:03 AM
From: bigbuk	Respond to of 122087

PANAMED CORPORATION (OTCBB: PANA), PART I – AFRICAN ADVENTURES June 24, 2002 Several internet newsletters have begun touting the prospects of PanaMed Corporation (OTCBB: PANA), an under-capitalized, over-the-counter company that has announced plans to test an unproven HIV/AIDS therapy in an unidentified African nation. For years, investors have been attracted to companies that claim to have developed treatments for AIDS and HIV. As we have seen however, when it comes to AIDS treatments, there can be a considerable chasm between promise and performance. (See HIV-VAC, Inc. - Can An AIDS Vaccine Possibly Be That Simplex?; HIV-VAC, Inc., Part II - Moving Forward In Reverse; and Ives Health Company, Inc. - Ives Wide Shut). PanaMed’s plans leave a lot to the imagination. Actually, they leave everything to the imagination. Is there any basis for the Company’s claims? How was the treatment developed, and by whom? Have there been clinical trials, and if so where? The promoters gloss over such details. Still, the newsletters claim to be “more than a little excited” about PanaMed. Perhaps that’s because the newsletter owner, Market Pathways Financial Relations Incorporated, received 40,000 restricted common shares of PanaMed common stock as payment for distributing these “reports” and “future advertising services.” On the other hand, investors will need considerably more information before they can share in the excitement. stockpatrol.com

To: KZAP who wrote (77275)	6/26/2002 11:26:33 AM
From: bigbuk	Read Replies (1) \| Respond to of 122087

PANAMED CORPORATION (OTCBB: PANA), PART II – PENNY KINGS FROM HEAVEN June 26, 2002 As we saw in Part I of this series, PanaMed Corporation (OTCBB: PANA) has been promoting plans to market a therapeutic product to treat HIV and AIDS. The Company has not said who developed the treatment, or where, or when. And, so far at least, the Company’s expectations have not been verified by independent clinical tests – unless you count the three AIDS patients who purportedly received the treatment in an “uncontrolled environment.” It’s not much to go on, is it? Team PanaMed Who are the scientists that developed this therapeutic treatment? What are their credentials? Where do they work? Have they written about their findings? Are they teaching at major hospitals or universities? Do they hold any patents on the process? Shouldn’t we expect them to be rushing to take credit? Wouldn’t you? PanaMed does not name a single individual who might have been involved with the development of Viro-Net, stating only that the product is “supplied” by Havel Investments. PanaMed still has not said whether Havel manufactures the product. If not, where is it coming from, and who is paying for it? stockpatrol.com